2025 Debate OD Session 2 - Sponsored

This webcast series and supporting materials were developed by the Chronic Conditions faculty in conjunction with OmniaMed Communications. The sponsoring companies have had no input into the agenda, speaker selection, presentations or collateral content, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible.

Jardiance® (empagliflozin) prescribing information for the United Kingdom.
Adverse event reporting information can be found at the bottom of this page.

Chronic Conditions 2025

Debate - On Demand

View the on demand video below

Presenting to your peers: Communicating effectively with healthcare professionals

Presenter: Dr Sarah Jarvis

This promotional symposium has been organised, funded and developed by Boehringer Ingelheim for UK healthcare professionals only.

Boehringer Ingelheim products will be discussed in this presentation.

PC-GB-111682 | June 2025

JARDIANCE® (empagliflozin)¹ is indicated in adults and children aged 10 years and above for the treatment of
insufficiently controlled T2D as an adjunct to diet and exercise:
• as monotherapy when metformin is considered inappropriate due to intolerance
• in addition to other medicinal products for the treatment of diabetes
JARDIANCE® (empagliflozin) is indicated in adults for the treatment of symptomatic chronic heart failure
JARDIANCE® (empagliflozin) is indicated in adults for the treatment of chronic kidney disease

Reference
1. JARDIANCE® (empagliflozin) Summary of Product Characteristics

Jardiance® (empagliflozin) prescribing information for the United Kingdom.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

PC-GB-111682 | June 2025